Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Status:
Not yet recruiting
Trial end date:
2037-04-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the
impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal
A hormone receptor-positive (HR+) metastatic breast cancer (MBC)